

02507819

Excellent paper. It gives a hope to patients not responding to standard FOLFIRINOX regime. I congratulate the authors.

Thank you

05244644

The manuscript entitled "Change in Neoadjuvant Chemotherapy could alter the Prognosis of Patients with Pancreatic Adenocarcinoma: a case report" present an excellent case report.

Thank you

01588784

This case report demonstrated that gemcitabine plus nab-paclitaxel may be considered as one of the treatment regimens for neoadjuvant chemotherapy for locally advanced pancreatic cancer, particularly for those FOLFIRINOX was not effective. Given the well-known poor survival, researches and trials on neoadjuvant chemotherapy for pancreatic cancer has been always of great concern. However, this paper does not seem to provide sufficient information for readers, so please be advised to revise or add the following points:

ABSTRACT

1) Background: First sentence can be omitted, because repeated phrases appeared in the following main text.

We omitted the first sentence now

2) Case presentation: The paragraph only described the imaging findings, and did not mention about the treatment regimen or clinical courses. More informative presentation is desired.

We added more information here

3) Conclusion: Readers may confuse whether gemcitabine plus nab-paclitaxel is effective as the second line treatment or the alternative regimen for neoadjuvant treatment.

We clarified this saying that Gemcitabine plus nab-paclitaxel can be used as an alternative regimen if FOLFIRINOX fails as the first line of treatment.

MAIN TEXT

Background

1) Second paragraph can be omitted and included in the Discussion.

Okay

2) Third paragraph needs references.

Okay, we added the reference

Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. *Cancers* (Basel). 2019 Jul 13;11(7):981. doi: 10.3390/cancers11070981. PMID: 31337045; PMCID: PMC6678351.

3) Fourth paragraph needs to clarify that chemotherapies were conducted in a neoadjuvant setting.

We added this clarification

#### Case presentation

1) Additional CT figures are needed for the status after FOLFIRINOX treatment. 2) Additional PET/CT figures are needed for the status after the exploratory laparotomy. 3) Did you mean frozen section for 'freezing test'??

4) Figure 3 did not match the corresponding sentence (rather reflects the last sentence).

5) On the whole, it is not easy to understand the timeline of the treatment course. For example, the interval from the gem-nab pac treatment to the second surgery was unknown (the authors mentioned the date May 2019). Furthermore, in the last sentence 'so far' did not specify the length of disease-free survival.

**We made the timeline evident now, improved the case presentation and sent the text for English revision.**

#### Discussion

1) It was well described, hopefully recent clinical trials may be added (for example, PREP-01 study; J Gastroenterol 2019 etc.) References 1) Ref. 5 and 9 were duplicated. 2) Ref. 18 and 19 were duplicated.

**All the references are correct now, thank you**

Abstract 1) Please add an explanation that R0 surgical resection was performed after the GEM plus nab-pac neoadjuvant treatment.

We added this information to the abstract.

Main text 1) Treatment: Please specify the time interval from the last session of GEM plus nab-pac treatment and the second surgery.

We specified the time interval now in our text.

2) Discussion: Ref 19 (Motoi et al.) describes the use of S-1 plus GEM for neoadjuvant treatment, not with FOLFIRINOX. Please indicate that FOLFIRINOX as well as other regimens have been recommended for the first treatment.

We corrected the reference and included another one to discuss the use of FOLFIRINOX as well as other regimens for the first treatment